Systech, a global leader in pharmaceutical serialization and traceability, announced the availability of two new integrated packaging solutions designed to...
CHARM Therapeutics (“CHARM”, “The Company”), a clinical-stage biotechnology company addressing resistance in acute myeloid leukemia...
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting,...
Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2 Statistically significant improvements ...
Biomapas, a leading integrated life sciences services provider, announces the acquisition of Pinnaxis, a global pharmacovigilance technology and consulting...
Strategic collaboration combines Italfarmaco’s leadership in HDAC biology and therapeutic development with VeriSIM Life’s Mechanistic AI dr...
Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2...
Beactica Therapeutics AB, a Swedish precision medicine company, announced the selection of BEA-28 as a preclinical candidate for its TEAD programme, which ...
The new microbiology laboratory and sterility testing suite are designed for GMP drug product applications. This addition is part of the broader Lexingt...
Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background Administered...
Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ...
AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBM...
Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, announced positive results from a prospective, multicenter randomized controlled tr...
Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duratio...
© 2026 Biopharma Boardroom. All Rights Reserved.
